EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib

Panli Cardona, Sandeep Dutta, Brett Houk

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1392 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Panli Cardona und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Liver-Specific Organic Anion Transporter 1, Solute Carrier Organic Anion Transporter Family Member 1B3, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotorasib is a small molecule that irreversibly inhibits the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein with a G12C amino acid substitution mutant protein. The impact of cytochrome P450 (CYP) 3A4 inhibition and induction on sotorasib pharmacokinetics (PKs) was evaluated in 2 separate studies in healthy volunteers (N = 14/study). The impact of CYP3A4 inhibition was interrogated utilizing repeat doses of 200 mg of itraconazole, a strong CYP3A4 inhibitor, on 360 mg of sotorasib PKs. The impact of CYP3A4 induction was interrogated utilizing multiple doses of 600 mg of rifampin, a strong CYP3A4 inducer. Additionally, the impact of organic anion transporting polypeptide (OATP) 1B1/3 inhibition on 960 mg of sotorasib PKs was interrogated after a single dose of 600 mg of rifampin. CYP3A4 inhibition did not significantly impact sotorasib C max but did lead to a 26% increase in sotorasib AUC inf . CYP3A4 induction decreased sotorasib C max by 35% and AUC inf by 51%. OATP1B1/3 inhibition decreased sotorasib C max and AUC inf by 16% and 23%, respectively. These results support that sotorasib can be given together with strong CYP3A4 and OATP1B1/3 inhibitors but the co‐administration of sotorasib and strong CYP3A4 inducers should be avoided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver-Specific Organic Anion Transporter 1Solute Carrier Organic Anion Transporter Family Member 1B3Cytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3ARifampinDrug InteractionsCytochrome P-450 CYP3A InducersHumansMaleAdultFemaleYoung AdultAdministration, OralMiddle AgedHealthy VolunteersArea Under CurveItraconazoleSpiro Compounds

Stichwörter der Autor:innen

CYP3A4KRAS inhibitordrug interactiononcologysotorasib

Substanzen

Liver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3Cytochrome P-450 CYP3A InhibitorsSLCO1B3 protein, humanCytochrome P-450 CYP3ARifampinCytochrome P-450 CYP3A InducersCYP3A4 protein, humanItraconazole

Autor:innen und Institutionen

  • Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA.

Zitieren

APA

Cardona, P., Dutta, S., & Houk, B. (2024). Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1392

Vancouver

Cardona P, Dutta S, Houk B. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1392

BibTeX
@article{Cardona2024,
  author = {Cardona, Panli and Dutta, Sandeep and Houk, Brett},
  title = {Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1392}
}
Kostenlos starten →